Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 5/2006

01-09-2006 | Guest Editorial

The global perspective of osteoporosis

The ILAR Lecture, June 2004, Berlin

Author: Anthony D. Woolf

Published in: Clinical Rheumatology | Issue 5/2006

Login to get access

Excerpt

Osteoporosis is now recognised as an important public health issue, but should it be a priority in all countries? To establish this, we have to understand what the burden is on individuals and societies across the globe at present and future trends. In addition, can it be treated and prevented effectively and affordably in all continents and cultures? How should resources be targeted to be most cost-effective in preventing fractures due to underlying osteoporosis? …
Literature
1.
Consensus Development Conference (1991) Prophylaxis and treatment of osteoporosis. Am J Med 90(1):107–110CrossRef
2.
World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a World Health Organization Study Group. WHO Technical Report Series No. 843. World Health Organization, Geneva
3.
4.
Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7(5):407–413PubMedCrossRef
5.
Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81(9):646–656PubMed
6.
World Health Organization (2003) Prevention and management of osteoporosis. WHO Technical Report Series No. 921. World Health Organization, Geneva
7.
World Health Organization (2003) The burden of musculoskeletal diseases at the start of the new millenium. WHO Technical Report Series No. 919. World Health Organization, Geneva
8.
Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27(5):585–590PubMedCrossRef
9.
Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM (2005) Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 20(2):185–194PubMedCrossRef
10.
Woolf AD, Pfleger B (2005) Burden of osteoporosis and fractures in developing countries. Curr Osteoporos Rep 3(3):84–91PubMedCrossRef
11.
van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29(6):517–522PubMedCrossRef
12.
Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15(11):897–902PubMedCrossRef
13.
Zebaze RM, Seeman E (2003) Epidemiology of hip and wrist fractures in Cameroon, Africa. Osteoporos Int 14(4):301–305PubMedCrossRef
14.
Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17(7):1237–1244PubMedCrossRef
15.
Lau EM, Lee JK, Suriwongpaisal P, Saw SM, Das De S, Khir A, Sambrook P (2001) The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int 12(3):239–243PubMedCrossRef
16.
O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European vertebral osteoporosis study. J Bone Miner Res 11(7):1010–1018PubMedCrossRef
17.
Silman AJ (2003) Risk factors for Colles’ fracture in men and women: results from the European prospective osteoporosis study. Osteoporos Int 14(3):213–218PubMed
18.
World Health Organization (2001) The International Classification of Functioning and Health (ICF). ISBN 92 4 154 542 9. World Health Organization, Geneva
19.
Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15(7):1384–1392PubMedCrossRef
20.
Sernbo I, Johnell O (1993) Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int 3(3):148–153PubMedCrossRef
21.
Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse AA (2004) Meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382PubMedCrossRef
22.
Cuddihy MT, Gabriel SE, Crowson CS, O’Fallon WM, Melton LJ III (1999) Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int 9(6):469–475PubMed
23.
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285(3):320–323 (Jan 17)PubMedCrossRef
24.
Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE, Quine S (2000) Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 320(7231):341–346 (Feb 5)PubMedCrossRef
25.
Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De Laet C (2005) The burden of hospitalised fractures in Sweden. Osteoporos Int 16(2):222–228PubMedCrossRef
26.
European Commission (1998) Report on osteoporosis in the European community: action for prevention. European Communities, Luxembourg
27.
World Health Organization (2005) Health and ageing: a discussion paper. WHO Department of Health Promotion NCDPS, Population Reference Bureau. http://​www.​prb.​org.​
28.
29.
World Health Organization (2002) The injury chart book. A graphical overview of the global burden of injuries. Department of Injuries and Violence Prevention, Noncommunicable Diseases and Mental Health Cluster. World Health Organization, Geneva
30.
31.
NICE (2005) Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology Appraisal 87
32.
U.S. Department of Health and Human Services (2004) Bone health and osteoporosis. A report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General, Rockville, MD. WE 225 B71259. http://​www.​surgeongeneral.​gov/​library
33.
Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 24(4):496–578
34.
35.
Disease Control Priorities Project. A World Bank/WHO/NIH Report (2006) (in press)
36.
Nguyen ND, Eisman JA, Nguyen TV (2006) Anti-hip fracture efficacy of bisphosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 21(1):340–349PubMedCrossRef
37.
Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O (2001) An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12(7):519–528PubMedCrossRef
38.
Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. study of osteoporotic fractures research group. N Engl J Med 332(12):767–773 (March 23)PubMedCrossRef
39.
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254–1259 (May 18)PubMed
40.
Ebeling PR, Akesson K (2006) Role of biochemical markers in the management of osteoporosis. In: Cooper C, Woolf AD (eds) Osteoporosis: Best practice and research compendium. Elsevier, Oxford, pp89–100
41.
Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30(1):251–258PubMedCrossRef
42.
Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16(6):581–589PubMedCrossRef
43.
44.
Metadata
Title
The global perspective of osteoporosis
The ILAR Lecture, June 2004, Berlin
Author
Anthony D. Woolf
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0265-7

Other articles of this Issue 5/2006

Clinical Rheumatology 5/2006 Go to the issue

Erratum

The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms

Original Article

Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice

Original Article

Partial construction of apoptotic pathway in PBMC obtained from active SLE patients and the significance of plasma TNF-α on this pathway

Original Article

A therapeutic education and functional readaptation program for Spanish patients with musculoskeletal chronic diseases

Case Report

Sjögren syndrome in a child: favorable response of the arthritis to TNFα blockade

Original Article

Toxic effects of povidone–iodine on synovial cell and articular cartilage
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits